Recent developments in the use of viruses as vaccine vectors have been facilitated by a
better understanding of viral biology. Advances occur as we gain greater insight into the …

In celebrating the 60th anniversary of the first isolation of human cytomegalovirus (HCMV),
we reflect on the merits and limitations of the viral strains currently being used to develop …

Recombinant adenoviruses are among the most promising tools for vaccine antigen
delivery. Recently, the development of new vectors has focused on serotypes to which the …

Current vaccine strategies against the asexual blood stage of Plasmodium falciparum are
mostly focused on well-studied merozoite antigens that induce immune responses after …

Human cytomegalovirus (HCMV) in clinical material cannot replicate efficiently in vitro until it
has adapted by mutation. Consequently, wild-type HCMV differ fundamentally from the …

Antiviral immune responses present a major hurdle to the efficacious use of oncolytic
adenoviruses as cancer treatments. Despite the existence of a highly immunosuppressive …

Human cytomegalovirus (HCMV) is the most common vertically transmitted infection
worldwide, yet there are no vaccines or therapeutics to prevent congenital HCMV (cCMV) …

NKG2D plays a major role in controlling immune responses through the regulation of natural
killer (NK) cells, αβ and γδ T-cell function. This activating receptor recognizes eight distinct …

Human adenoviruses (Ads) have long been studied in the basic virology field and are
exploited as vectors for gene therapy, vaccination, and oncolytic therapy. Ads are usually …

The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for
oncolytic virotherapy, since it provided unequivocal evidence for the long-touted potential of …